Homepage > Company > Media > Pharma News > 2024 > Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

It is the second collaboration between the two entities, building on the partnership that began in April 2024. The new global licencing agreement aims to develop an additional oncology biosimilar, reinforcing the alliance between Teva and mAbxience.

By combining their expertise and resources, the companies are committed to fostering innovation and improving healthcare accessibility for patients globally.

The agreement grants Teva exclusive rights for several markets, including Europe and the US. It is in line with mAbxience’s strategy for expansion across the globe and reflects Teva’s efforts to grow its portfolio of biosimilars through strategic partnerships. As per the agreement, mAbxience will lead the development and manufacturing of the biosimilar, utilising its advanced certified good manufacturing practice-compliant (cGMP) facilities in Argentina and Spain.

Teva will be responsible for obtaining regulatory approvals and managing the commercialisation in the specified markets, aiming to provide access to this vital oncology treatment to patients worldwide.

Teva Pharmaceuticals has settled with the city of Baltimore in the US for $80m in September 2024, regarding its involvement in the opioid crisis. This settlement comes after Baltimore chose to opt out of a broader national case the previous year.

Read also

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China&...

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a...

Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), Gilead has decided to walk away from a $785 million biobucks deal in the...

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

AUS Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth BioTherapeutics’ first-line Barth syndrome drug, despite a trial studying the drug n...